Investigation of clinical application of everolimus in the treatment of advanced breast cancer
Objective To investigate and analyze the prescriptions/orders of everolimus for patients with advanced breast cancer in order to promote further rational application.Methods Relevant prescriptions/medical orders from 13 medical institu-tions from January 2018 to February 2022 were collected,and the dosage,medication duration,combined medication,and average daily dose were analyzed.Results A total of 2517 patients with advanced breast cancer were included.12.7%,47.3%and 4.0%of the investigated patients were given everolimusat 10.0 mg qd,5.0 mg qd,and 2.5 mg qd,respectively.Everolimus was mainly used in combination with aromatic amine enzyme inhibitors(AIs)and estrogen receptor(ER)antago-nists,and 42.7%of the patients chose exemestane.The average daily dose of everolimus in the combination group was lower than that in the non-combination group,and in specific,the average daily dose of everolimus in the combined exemestane group was 6.0 mg.Conclusion Everolimus is usually adopted by combined use,and the average daily dose of everolimus is significantly lower than the recommended dose in the manual,resulting in the daily average cost far lower than expected,and the clinical application has evidence-based support.
everolimusadvanced breast cancerendocrine therapycombined medicationaverage daily dose
NETL
NSTL
万方数据
